ЯЧфдцб 68 2 6 6 5 4 7 Email naseri@shahedacir 1* 1 2 4 5 6 7 (MS 8 ЯцуЧхфЧух ксуэ цхдэ ЯЧфд Чх дчхя гчс хчбяху дучбх 68 ЧбЯэШхдЪ 1 цецсў 8490 ЧбгЧс ЧесЧЭЧЪў 84121 ЯбэЧнЪ ЧесЧЭЧЪў 85128 аэбдў 85 2 59 wwwsidir
( (Relapsing MS (Secondary Progressive 1 SP Remitting RR 2001 ( 18 2 ] 4 ( gait 5 [ 1 (Relapse 2 4 5 ( 6 7 8 (Fixed-Tendon contracture 9 MS [1-1] MS [114-22] Ћ Л [2] [24] - 1 68 68 wwwsidir
68 Cr SGOT (ESR (UN SGPT (placebo 50 ( - 8 (=010 =005 (wash out ( ( = X1 =X (match ( =X2 (X - (X1 (X (X2 (X1ЁX2 - Л Ћ Л Ћ 8 Pvalue 005 18 20 (19 56 17 ( CRP wwwsidir
( (2 CRP ESR (+ 4 UN Cr SGOT SGPT (4 5 767 81 585 141 002 (X-X2 075 99 411 1 5159 11015 789 8187 1228 992 (X-X1 (X1-X2 18 18 404з106 718з10 417 15 277з10 855 814 855 166 002 109 768 821 122 69 054 41 4 22 974 466з106 71з10 4114 128 (297 45 4 14 1 2 (RC (1 (WC 116 84 2019 1059 015 + 2711з10 ( X1 (p=002 11289 777 8489 14 687 1 ( ( ( ( ( 046 29 7 201 579 462з106 708з10 4026 1290 268з10 2 ( ( ( ( ( + 68 wwwsidir
68 92 044 046 758 0 (X1-X2 942 128 744 02 14017 424 946 1085 0 (X-X2 (X-X1 (X1-X2 2264 225 240 078 05 06 055 181 066 (X-X2 (X-X1 1400 4 959 1707 017 + 17 01 069 15 09 1406 425 966 1622 1 ( ( ( ESR (mmh CRP (score 1+ to 4+ 921 1064 687 015 2206 289 2192 075 67 2 [25-28] (Follow up + 71 1882 758 011 1888 2209 2109 028 4 SGOT (ul SGPT (ul UN (mgdl Cr (mgdl 50 mgkg2500 [2] wwwsidir
14 Whitmarsh Thomas E Homeopathy in multiple sclerosis Complementary Therapies in Nursing and Midwifery Volume 9 Issue 1 February 200 pp5-9 15 Hunly Ernest E Complementary and alternative therapies for treating multiple sclerosis symptoms a systematic review Complementary therapy medicine 2000 jun 8(2 97-105 16 Pucci E Cartechini E Taus C Guiliani G why physicians need to look more closely at the use of Complementary and alternative medicine by multiple sclerosis patients Eur J Neurol 2004 pr 11(426-7 17 Stuifbergen K Harrison TC Complementary and alternative therapy use in persons with multiple sclerosis Rehabil Nurs 200 28(5141-7 18 WHO Traditional medicine strategy 2002-2005 Geneva 2002 1-4-47 19 Simile Ni H Hardy C M Utilization of complementary and alternative medicine by United States adults results from the 1999 national health interview survey Med Care 2002 pr; 40(4 5-8 20 Newland P The use and effectiveness of alternative therapies in multiple sclerosis J Neurosci Nurs 1999 Feb; 1(14-6 21 Nayak S Matheis RJ Schoenberger NE Shiflett SC Use of unconventional therapies by individuals with multiple sclerosis Clin Rehabil 200;17(2181-91 22 Stuifbergen K Harrison TC Complementary and alternative therapy use in persons with multiple sclerosis Rehabil Nurs 200 Sep-Oct;28(5141-7 11-14 52 11 (Rat 18 2 24 Casarett and Doull's Toxicology The basic science of poisons Klaassen C (editor McGraw-Hill 2001 92 25 Tremlett H Yoshida E Oger J Liver injury associated with the beta interferons for MS Neurology 2004; 62621 26 Duchini utoimmune hepatitis and interferon beta- 1a for multiple sclerosis m J Gastroenterol 2002; 97767768 27 ayas Rieckmann P Managing the dverse Effects of Interferon Therapy in Multiple Sclerosis Drug Safety 2000 22(2 149-159(11 28 Rieckmann P O'Connor P Francis G Wetherill G; lteri E Haematological Effects of Interferon-1a (RebifЎ Therapy in Multiple Sclerosis Drug Safety 2004 27(10 745-756 1 raunwald E Fauci S Harrison s principles of internal medicine 16 th edition 2005 Mc Grow-Hill publication 2461-2470 2 Coyl PK Hammad M tlas of multiple sclerosis 200 science press London1 grawal YP Low dose naltrexone therapy in multiple sclerosis Medical Hypotheses 2005 64 721724 4 Galetta Steven L Markowitz Clyde US FD- pproved Disease-Modifying Treatments for Multiple Sclerosis Review of dverse Effect Profiles CNS Drugs 2005; 19 ( 29-252 5 Killestein J Polman C Current trials in multiple sclerosis established evidence and future hopes Current Opinion in Neurology 2005 18(25-260 6 Howard L Weiner Immunosuppressive treatment in multiple sclerosis Journal of the Neurological Sciences 2004 22 1 11 7 Zivadinov R et al longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a Journal of the Neurological Sciences 200 216 11 118 8 Miltenburger C Kobelt G Quality of life and cost of multiple sclerosis Clinical neurology and neurosurgery 2002 104 272-275 9 Zajicek J Fox P Sanders H Wright D et al Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis multicentre randomized placebo-controlled trial The lancet Nov 8 200 62 995 1517 10 gents for multiple sclerosis The Cochrane Database of Systematic Reviews 200 Issue 4 11 Chilcott J McCabe C Tappenden P O'Hagan Cooper N Keith brams et al Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis MJ 200 VOL 26 12 Polman C Uitdehaag Drug treatment of multiple sclerosis MJ 2000; 21; 490-494 80-81 20 517 82 1 68 wwwsidir